What Is CLIA? CLIA Certification, Types, and CMS-116 Guide

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) is a federal regulatory program administered by the Centers for Medicare & Medicaid Services (CMS) that establishes quality standards for all laboratory testing performed on specimens derived from the human body. Under federal law, any facility in the United States that examines human specimens to provide information for the diagnosis, prevention, or treatment of disease, or for the assessment of health, must obtain a valid CLIA certificate before reporting patient-specific results. Depending on the analytical complexity of the test menu, laboratories must secure one of five certificate types—Certificate of Waiver, Provider-Performed Microscopy Procedures, Certificate of Registration, Certificate of Compliance, or Certificate of Accreditation—by submitting Form CMS-116 to their designated State Survey Agency.

Key takeaways

• Universal Federal Mandate: Any facility testing human specimens to inform clinical diagnosis, management, or health assessment must hold a CLIA certificate under 42 CFR Part 493 [0]. Pure research laboratories are exempt only if patient-specific results are never reported for clinical care.
• Five Certificate Tiers: Testing complexity dictates the certificate pathway. Simple, low-risk tests fall under a Certificate of Waiver, while non-waived testing (moderate complexity, high complexity, and all laboratory-developed tests) requires a Certificate of Registration followed by either a Certificate of Compliance (state inspection) or a Certificate of Accreditation (deemed private accreditor).
• High Complexity by Default: All laboratory-developed tests (LDTs) and off-label modifications to FDA-cleared assays are categorized by default as high complexity, requiring full analytical validation and rigorous personnel qualifications.
• The CMS-116 Pathway: Certification begins by filing Form CMS-116 [0] with the State Survey Agency where the physical laboratory is located, not directly with federal CMS headquarters.
• Updated Personnel and Fee Rules: CMS Final Rule CMS-3326-F introduced updated biennial fee structures, alternative sanctions for waived laboratories, modernized doctoral qualifications (including recognition of the Doctor of Clinical Laboratory Science), and revised degree requirements across supervisory roles.

Statutory Authority and the Scope of CLIA Oversight

CLIA was established under Section 353 of the Public Health Service Act (42 U.S.C. § 263a) and is codified in the Code of Federal Regulations at 42 CFR Part 493 [0]. The statute creates a uniform federal baseline for diagnostic accuracy, reliability, and timeliness across every clinical testing site in the United States, regardless of whether testing occurs in a tertiary hospital, an independent commercial reference laboratory, a physician office, or a biotechnology startup.

Three federal agencies share operational responsibility for CLIA:

1. Centers for Medicare & Medicaid Services (CMS): Oversees program administration, issues certificates, collects user fees, conducts enforcement, and monitors State Survey Agencies and deemed accreditation organizations.
2. Food and Drug Administration (FDA): Categorizes diagnostic commercial test systems into regulatory complexity levels (waived, moderate complexity, or high complexity) through its premarket review processes and the FDA CLIA Categorization Database [0].
3. Centers for Disease Control and Prevention (CDC): Provides scientific and technical analysis, supports the Clinical Laboratory Improvement Advisory Committee (CLIAC), and conducts research on laboratory quality standards.

The Research Exemption and When CLIA Applies

A common point of ambiguity arises in translational research, clinical trials, and early-stage assay development. Under 42 CFR § 493.3(b)(2), facilities that examine human specimens solely for research purposes—and do not report patient-specific results for the diagnosis, prevention, or treatment of any disease or impairment, or the assessment of the health of individual patients—are exempt from CLIA requirements.

However, the legal threshold is strict. The moment an investigational laboratory reports a patient-identified result to a treating physician, clinical investigator, or patient to guide therapeutic decisions, medical management, or trial stratification, the facility crosses out of pure research and must hold an active CLIA certificate.

Understanding the Five CLIA Certificate Types

Federal regulations define five distinct certificate categories under 42 CFR Part 493, Subpart B. The appropriate certificate depends on the highest complexity level among all tests on the laboratory’s active menu.

Proposed Test Menu
       │
       ├─► Waived Tests Only ─────────────────────────► Certificate of Waiver (COW)
       │
       ├─► Waived + Select Microscopic Tests ─────────► Provider-Performed Microscopy (PPM)
       │
       └─► Moderate Complexity, High Complexity,
           or Laboratory-Developed Tests (LDTs)
                 │
                 ▼
         Certificate of Registration (COR)
                 │
                 ├─► State Agency Biennial Inspection ──► Certificate of Compliance (COC)
                 │
                 └─► Deemed Accreditor (e.g., CAP) ────► Certificate of Accreditation (COA)

1. Certificate of Waiver (COW)

A Certificate of Waiver permits a facility to perform only tests categorized by the FDA as waived. Waived tests are defined by statute as simple laboratory examinations and procedures that have an insignificant risk of an erroneous result. Common examples include dipstick urinalysis, rapid point-of-care influenza or COVID-19 antigen assays, and capillary blood glucose monitoring.

Laboratories operating under a COW are not subject to routine biennial inspections, but they must:

• Pay biennial certificate fees to CMS.
• Strictly follow the manufacturer's current Instructions for Use (IFU).
• Permit ad-hoc inspections if CMS investigates a complaint or evaluates public health risks.

Regulatory Note: If a laboratory holding a COW alters a manufacturer's protocol in any way—such as utilizing an unvalidated specimen matrix or modifying incubation periods—the test is automatically reclassified as high complexity. Operating outside the IFU under a Certificate of Waiver constitutes a direct regulatory violation.

2. Certificate for Provider-Performed Microscopy (PPM) Procedures

The PPM certificate is a specialized subset of moderate-complexity testing. It allows physicians, mid-level practitioners (nurse practitioners, physician assistants, certified nurse-midwives), or dentists to perform a narrow list of specified microscopic procedures during an in-person patient encounter.

Permissible PPM procedures include:

• Wet mount preparations (for detecting Trichomonas, yeast, or clue cells)
• Potassium hydroxide (KOH) preparations
• Pinworm examinations
• Fern tests
• Post-coital examinations of cervical mucus
• Urine sediment examinations

PPM facilities may also conduct waived tests under this certificate. While routine biennial surveys are generally not scheduled, the laboratory must adhere to federal quality control, proficiency testing, and personnel requirements for moderate-complexity testing.

3. Certificate of Registration (COR)

A Certificate of Registration is a temporary certificate issued to newly established laboratories planning to perform non-waived (moderate- and/or high-complexity) testing, including laboratory-developed tests (LDTs).

A COR allows the laboratory to:

• Validate analytical methods and establish performance specifications under 42 CFR § 493.1253.
• Finalize standard operating procedures and train testing personnel.
• Begin patient testing and report clinical results while awaiting its initial baseline on-site inspection.

The COR remains active until the laboratory completes its initial survey—conducted either by the State Survey Agency or an approved accreditation organization—and either transitions to a Certificate of Compliance or Certificate of Accreditation, or is found non-compliant.

4. Certificate of Compliance (COC)

A Certificate of Compliance is issued to laboratories performing moderate- and/or high-complexity testing after an on-site inspection conducted directly by surveyors from the State Survey Agency (acting on behalf of CMS).

Surveyors evaluate the facility against all operational subparts of 42 CFR Part 493, including:

• General and specific quality control (Subpart K)
• Proficiency testing enrollment and performance (Subpart H)
• Facility administration and physical environment (Subpart J)
• Personnel qualifications and competency assessments (Subpart M)
• Quality assessment systems (Subpart K)

Laboratories holding a COC undergo unannounced on-site surveys every two years conducted by state inspectors.

5. Certificate of Accreditation (COA)

A Certificate of Accreditation is issued to moderate- and high-complexity laboratories that elect to be inspected by a CMS-approved, non-profit private Accreditation Organization (AO) instead of the State Survey Agency. Under Section 353(e) of the Public Health Service Act, CMS grants "deemed status" to accrediting bodies whose proprietary standards meet or exceed federal CLIA regulations.

Widely recognized CMS-approved accrediting organizations include:

• College of American Pathologists (CAP): Commonly chosen by academic medical centers, complex molecular pathology laboratories, and reference facilities due to its granular, specialty-specific checklists.
• COLA: Frequently utilized by independent commercial laboratories, physician-owned clinics, and mid-sized health systems.
• The Joint Commission (TJC): Often selected by integrated hospital systems seeking unified accreditation across clinical and hospital operations.
• Accreditation Association for Hospitals and Health Systems (AAHHS/HFAP).

Laboratories holding a COA must maintain continuous compliance with both CLIA statutory minimums and the specific checklist requirements of their chosen accrediting organization, undergoing biennial deemed surveys.

CLIA Certificate Types: Comparative Matrix

Step-by-Step Pathway: How Laboratories Get CLIA Certified

Securing a CLIA certificate is a structured administrative and technical process. Missteps in completing documentation or misidentifying personnel qualifications frequently cause months of administrative delays.

Step 1: Determine Menu Complexity (Waived vs. Moderate vs. High / LDTs)
  │
Step 2: Appoint & Document Qualified Personnel (42 CFR Part 493 Subpart M)
  │
Step 3: Complete CMS-116 Application Form
  │
Step 4: Identify & Prepare State-Specific Licensure (e.g., CA, NY, FL, MD)
  │
Step 5: Submit Dossier to the State Survey Agency (Physical Location)
  │
Step 6: Pay CMS Fee Coupon & Receive 10-Digit CLIA ID (Certificate Issued)
  │
Step 7: Perform Method Validation, Enroll in PT & Complete Initial Survey (COR -> COC/COA)

Step 1: Define Test Menu and Complexity Classification

Before drafting application forms, the laboratory must classify every planned test:

• Waived: Confirm waiver status via the FDA database.
• Moderate or High Complexity: Review commercial package inserts for FDA classification.
• Laboratory-Developed Tests (LDTs): Any in-house assay developed from individual reagents, or any modified commercial assay, is categorized as high complexity.

Assay characterization dictates whether the facility applies for a COW, PPM, or non-waived certificate (COR leading to COC or COA).

Step 2: Establish the Laboratory Leadership Structure

For moderate- and high-complexity testing, laboratories must designate qualified individuals for statutorily defined roles under 42 CFR Part 493, Subpart M:

• Laboratory Director (LD): Holds overall regulatory, operational, and scientific responsibility.
• Clinical Consultant (CC): Provides clinical consultation regarding test selection and interpretation.
• Technical Supervisor (TS) / Technical Consultant (TC): Establishes quality control standards and evaluates analytical methodologies (Technical Supervisor for high complexity; Technical Consultant for moderate complexity).
• General Supervisor (GS): Provides day-to-day supervision of high-complexity testing personnel and reporting.
• Testing Personnel (TP): Qualified laboratory technicians or technologists performing hands-on analysis.

One individual may hold multiple roles if they satisfy the distinct regulatory qualification criteria for each position.

Step 3: Complete Form CMS-116

The official entry vehicle is Form CMS-116 (CLIA Application for Certification) [0]. Key sections require:

• Section I (General Information): Facility physical address (a CLIA certificate applies to a single physical location), federal tax identification number (EIN), contact details, and corporate ownership structure.
• Section II (Implementation Type): Identification of initial certification, change of ownership (CHOW), location amendment, or certificate type change.
• Section III (Type of Certificate Requested): Selection of COW, PPM, Compliance (state survey), or Accreditation (naming the specific accrediting body).
• Section V–VI (Specialties and Test Volumes): Detailed breakdown of planned test volumes categorized by clinical specialty (e.g., Chemistry, Hematology, Microbiology, Molecular Pathology) and estimated annual numbers.
• Section VII (Director Qualification Documentation): Direct submission of the Laboratory Director's curriculum vitae, state medical/laboratory licenses, and relevant board certifications.

Step 4: Account for State-Specific Licensure Requirements

A CLIA certificate is a federal baseline, but state laws operate concurrently. Multiple states maintain their own clinical laboratory licensing frameworks that require independent documentation, personnel licensing, and separate fees prior to or concurrent with CLIA processing:

• California: Requires a Clinical Laboratory License through the California Department of Public Health (CDPH) Laboratory Field Services (LFS).
• New York: Operates the Clinical Laboratory Evaluation Program (CLEP), requiring a separate Department of Health permit and individual Certificate of Qualification (CQ) for directors.
• Other Licensure States: Florida, Maryland, Pennsylvania, and Rhode Island, among others, mandate state facility licenses.

Furthermore, three states—New York, Washington, and Rhode Island—currently operate CLIA-exempt state programs under federal approval. Laboratories located within Washington and New York submit documentation directly to their state programs, which administer regulations evaluated by CMS as equivalent to or more stringent than CLIA.

Step 5: Submit Application to the Local State Survey Agency

Form CMS-116 is not filed with federal CMS regional offices. Completed dossiers must be submitted to the specific State Survey Agency governing the physical location of the testing facility. Laboratories can identify their regional intake office through the CMS Directory of State Survey Agencies.

Step 6: Fee Assessment and Initial Certificate Issuance

Following initial administrative review:

1. The State Survey Agency enters laboratory data into the federal Automated Survey Processing Environment (ASPEN) database.
2. CMS generates a fee coupon mailed or emailed to the applicant.
3. Upon payment of the initial fee, CMS issues a 10-digit CLIA identification number alongside the appropriate initial certificate (COW, PPM, or COR).
4. A laboratory issued a Certificate of Registration may begin analytical validation, staff orientation, and active patient testing.

Step 7: The Initial Survey and Certificate Conversion

For facilities holding a Certificate of Registration, the final step involves converting the COR into an ongoing Certificate of Compliance or Certificate of Accreditation:

• Timing: The initial survey typically occurs between 3 and 12 months after the COR is active, ensuring the laboratory has generated sufficient testing data, proficiency testing records, and quality control metrics for surveyors to evaluate.
• Inspection Scope: Surveyors assess method performance specifications (analytical validation data under 42 CFR § 493.1253), personnel competency records, standard operating procedures, instrument calibration verifications, and specimen logs.
• Resolution: Upon successful survey completion and correction of any cited deficiencies via an approved Plan of Correction (PoC), CMS issues the laboratory its formal Certificate of Compliance or Certificate of Accreditation, valid for two years.

Personnel Qualifications Under the Modernized CLIA Final Rule

In late 2023, CMS published its long-anticipated Final Rule (CMS-3326-F [0]), enacting the most comprehensive update to CLIA regulations in several decades. While fee adjustments and expanded sanction authorities took effect in early 2024, significant structural updates governing personnel qualifications under 42 CFR Part 493, Subpart M went into full effect on December 28, 2024.

Key updates governing laboratory leadership and operations include:

• Recognition of the Doctor of Clinical Laboratory Science (DCLS): The revised rule explicitly incorporates the DCLS degree as an approved qualifying doctoral degree for laboratory directorship, placing clinical laboratory doctoral practitioners alongside traditional Ph.D. and M.D./D.O. pathways.
• Clarification of Academic Coursework: CMS established unambiguous criteria regarding what constitutes an equivalent biological or chemical science degree, defining precise semester-hour thresholds in biology, chemistry, and clinical laboratory sciences to eliminate prior regional variability across State Survey Agencies.
• Mid-Level Roles and Nursing Credentials: The rule permits individuals with a Bachelor of Science in Nursing (BSN) and relevant clinical laboratory training to perform moderate-complexity testing. However, the rule explicitly confirmed that nursing degrees do not qualify an individual to serve as a high-complexity laboratory director, technical supervisor, or general supervisor without meeting standard biological science degree requirements.
• Alternative Sanctions for Certificate of Waiver Labs: Historically, CMS could only suspend or revoke a Certificate of Waiver if non-compliance was uncovered. The revised regulations allow CMS to impose alternative intermediate sanctions, including civil monetary penalties (CMPs) and directed plans of correction, increasing regulatory oversight over waived testing operations.

Navigating these statutory updates requires structured oversight. Diagnostic facilities often align their compliance operations through external regulatory and laboratory compliance support to ensure that organizational charts and personnel qualifications meet active federal and state standards.

CLIA and Laboratory-Developed Tests (LDTs)

A frequent point of discussion among clinical assay developers is the interplay between CLIA and FDA jurisdiction over Laboratory-Developed Tests. While the FDA has asserted device-level oversight through its May 2024 In Vitro Diagnostic Products final rule, CLIA remains the bedrock federal statutory standard governing laboratory facilities, testing personnel, operational workflows, and analytical quality systems.

Regardless of premarket authorization pathways, clinical trial design, or medical device categorization under the Food, Drug, and Cosmetic Act (FD&C Act), every clinical diagnostic laboratory performing non-waived testing within the United States must:

1. Maintain an active CLIA Certificate of Registration, Compliance, or Accreditation.
2. Establish and document analytical performance specifications under 42 CFR § 493.1253 (accuracy, precision, analytical sensitivity, analytical specificity, reportable range, reference intervals, and calibration verification).
3. Enroll in an approved Proficiency Testing (PT) program for all regulated analytes on its active test menu.
4. Re-verify operational quality continuously through formal internal audits and biennial inspections.

Achieving and sustaining this regulatory operational posture requires a disciplined quality management system that links laboratory architecture directly to federal standards.

Summary of the Two-Year CLIA Survey Lifecycle

Holding a Certificate of Compliance or Accreditation initiates a continuous, biennial compliance cycle:

Month 0: Initial Application (CMS-116 filed)
  │
Month 1–2: Fee Paid & Certificate of Registration (COR) Issued
  │
Month 3–12: Analytical Validations, PT Enrollment, Routine Patient Testing
  │
Month 6–12: Initial Survey (State Survey Agency or Accrediting Organization)
  │
Year 1: Deficiencies Cleared via Plan of Correction; COC or COA Issued
  │
Year 2: Biennial Fee Coupon Issued by CMS
  │
Year 2 (End): Routine Unannounced Re-survey (Cycle Repeats Every 2 Years)

Maintaining inspection readiness throughout this two-year cycle requires ongoing quality assessment, documented biannual instrument calibration verifications, semiannual testing personnel competency assessments, and rigorous tracking of pre-analytical, analytical, and post-analytical quality indicators. Structuring these processes early prevents severe operational disruption during unannounced federal or deemed accreditation inspections.

How Priestly Consulting Can Help

Establishing a new clinical laboratory or transitioning a novel diagnostic method from research to clinical testing involves complex regulatory and operational workflows. Priestly Consulting provides strategic advisory and documentation support to clinical laboratories, molecular diagnostic developers, and biotechnology companies navigating the CLIA application and operational landscape.

Our team assists organizations with Form CMS-116 preparation, state laboratory licensing dossiers, personnel qualification gap analyses, and the development of quality management systems aligned with 42 CFR Part 493. We also provide technical guidance on standard operating procedure formulation, analytical validation protocols, and inspection readiness for both state surveys and deemed accreditation organizations. As an independent consulting firm, Priestly Consulting provides scientific, operational, and regulatory documentation advisory services; we do not operate a clinical testing facility, provide legal counsel, or guarantee regulatory outcomes.

To discuss your laboratory’s certification pathway or quality management framework, schedule a consultation with our advisory team.